Gastroenterology

The cumulative probabilities of treatment initiation after meeting the criteria was not significantly different between the different racial groups and the incidence of major adverse liver outcomes was 0.1 per 100 person-years and did not differ by race.

Nonoperative management was associated with a 3.72% decrease in the risk of complications and a 1.82% increase in mortality in patients who were aged 65 years and older.

From a novel topical gene therapy to a multi-pathway targeting HF drug, the second quarter of 2023 is laden with interesting regulatory decisions.

Patients with no prior colonoscopy had significantly higher all-cause mortality and colorectal cancer specific mortality compared to patients with detected colorectal cancer.

Increased age, male sex, COPD, CHF, dependent functional status, and C. difficile infection were associated with increased mortality within 30 days of surgery.

The incidence of mPDAI-defined remission at week 14 was 31% in the vedolizumab group, compared to 10% in the placebo group.

The majority of patients felt it was important for healthcare providers talk to them about the symptoms, possible treatments. In addition, most patients are not prescribed a medication right away.

Among 1660 cases with only PCR data, the cycle threshold was significantly associated with recurrence-free survival.

A nearly two-fold increase or decrease in liver stiffness would be required to confidently represent a change in the underlying fibrosis.

At the 6 month follow-up visit, all participants had stable folic acid levels without macrocytic anemia and the monthly questionnaires showed no increase in symptoms or adverse events reported.

Patients at a risk of malnutrition had a significantly lower mean of albumin, as well as significantly increased proportion of patients with CRP >5 mg/L.

There is a June 22 PDUFA date for obeticholic acid, which if approved would become the first FDA-approved treatment for NASH.

The treatment is a first-in-class peptide derived from mTB Chaperonin 60.1 that is often involved in resetting the immune system. The treatment is being evaluated in patients with eosinophilic esophagitis and allergen sensitivity.

The 2 groups had similar data for any endoscopic recurrence and severe endoscopic recurrence at the first endoscopic evaluation.

Acute severe ulcerative colitis and a greater number of biologics precoloectomy were linked to an increased probability of acute pouchitis, while older age at colectomy was associated with a decreased probability of acute pouchitis.

The results from the INSPIRE trial show risankizumab met all primary and secondary endpoints in treating adult patients with moderately to severely active ulcerative colitis.

No single biomarker or multimarker score significantly reached the predefined acceptability thresholds for patients with NASH and clinically significant fibrosis.

In the infliximab reference group, the persistence at month 12 was 94% for Crohn’s disease and 92.8% for ulcerative colitis.

New phase 2 trial results suggest semaglutide 2·4 mg once weekly did not improve fibrosis without worsening of NASH in patients with NASH-related compensated cirrhosis.

The mean change from baseline to the day of the first masked gluten challenge in total gastrointestinal scores for the non-homozygous Nexvax2 group was 2.86 compared to 2.63 for the non-homozygous placebo group.

An investigation utilizing machine learning (Recursive Ensemble Feature Selection, REFS) identifies potential biomarkers for asthma control in pediatric patients.

The overall survival after adjusting for tumor stage showed tumor adipose feature was independently prognostic as both a binary feature and as a semiquantitative categorical feature.

The prevalence of CDI in southern China was 11.0% and 13.6% in northern China.

The results show concomitant recurrent CDI was associated with an IBD flare in 54% of participants. Of this group, 63% received IBD remission-induction therapy before FMT.

Recent data during ECCO 23 show ustekinumab results in higher rates of clinical remission and clinical response in patients with inflammatory bowel disease.